ABC | Volume 114, Nº5, May 2020

Statement Brazilian Cardiology Society Statement for Management of Pregnancy and Family Planning in Women with Heart Disease – 2020 Arq Bras Cardiol. 2020; 114(5):849-942 412. Katz V, Balderston K, DeFreest M. Perimortem cesarean delivery: were our assumptions correct? Am J Obstet Gynecol. 2005;192(6):1916-20; discussion 1920-1. 413. DrenthenW, Boersma E, Balci A, Moons P, Roos-Hesselink JW, Mulder BJ, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J. 2010;31(17):2124-32. 414. Balci A, Sollie-Szarynska KM, van der Bijl AG, Ruys TP, Mulder BJ, Roos-Hesselink JW, et al. Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease. Heart. 2014;100(17):1373-81. 415. Thorne S, Nelson-Piercy C, MacGregor A, Gibbs S, Crowhurst J, Panay N, et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care. 2006;32(2):75-81. 416. Van Hagen IM, Boersma E, Johnson MR, Thorne SA, Parsonage WA, Escribano Subías P, et al. Global cardiac risk assessment in the registry of pregnancy and cardiac disease: results of a registry from the european society of cardiology. Eur J Heart Fail. 2016;18(5):523-33. 417. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. Medical Eligibility Criteria for ContraceptiveUse, 2016. MMWR Recomm Rep. 2016;65(3):1-103. 418. BonnemaRA,McNamaraMC,SpencerAL.Contraceptionchoicesinwomen with underlyingmedical conditions. AmFamPhysician. 2010;82(6):621-8. 419. Raccah-Tebeka B, Plu-Bureau G. Long-acting reversible contraception. Rev Prat. 2018;68(4):387-91. 420. Amies Oelschlager AM, Micks EA, Debiec KE, Nizamic T, Mantrala MD, Prager SW. Long acting reversible contraception in adolescents with cardiovascular conditions. J Pediatr Adolesc Gynecol. 2014;27(6):353-5. 421. World Health Organization (WHO). Medical eligibility criteria for contraceptive use. 5th ed. Geneva; 2015. 422. AvilaWS, GrinbergM, Melo NR, Pinotti JA, Pileggi F. Contraceptive use in women with heart disease. Arq Bras Cardiol. 1996;66(4):205-11. 423. Bonassi Machado R, Gandolpho AC, Santana N, Bocardo RC, Palandri N, Morassutti Machado R. Contraception for women with heart disease: an update. Minerva Ginecol. 2017;69(3):259-68. 424. Øyen N, Diaz LJ, Leirgul E, Boyd HA, Priest J, Mathiesen ER, et al. Prepregnancy Diabetes and Offspring Risk of Congenital Heart Disease: A Nationwide Cohort Study. Circulation. 2016;133(23):2243-53. 425. Kalra B, Kalra S. Contraception in women with diabetes. J PakMed Assoc. 2017;67(3):482-3. 426. Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. Heart. 2006;92(10):1520-5. 427. Hudsmith L, Thorne S. Contraception in women with cardiac disease. Womens Health (Lond). 2007;3(6):711-7. 428. Weill A, Dalichampt M, Raguideau F, Ricordeau P, Blotière PO, Rudant J, et al.Lowdoseoestrogencombinedoralcontraceptionandriskofpulmonary embolism, stroke, andmyocardial infarction in fivemillion Frenchwomen: cohort study. BMJ. 2016 May;353:i2002. 429. JudgeCP,ZhaoX,SileanuFE,MorMK,BorreroS.Medicalcontraindications to estrogen and contraceptive use among women veterans. Am J Obstet Gynecol. 2018;218(2):234.e1-234.e9. 430. Rocha AL, Campos RR, Miranda MM, Raspante LB, Carneiro MM, Vieira CS, et al. Safety of hormonal contraception for obesewomen. Expert Opin Drug Saf. 2017;16(12):1387-93. 431. Ueda Y, Kamiya CA, Horiuchi C, Miyoshi T, Hazama R, Tsuritani M, et al. Safety and efficacy of a 52-mg levonorgestrel-releasing intrauterine system in women with cardiovascular disease. J Obstet Gynaecol Res. 2019;45(2):382-8. 432. Hinze A, Kutty S, Sayles H, Sandene EK, Meza J, Kugler JD. Reproductive and contraceptive counseling received by adult women with congenital heart disease: a risk-based analysis. Congenital Heart Dis. 2013;8(1):20-31. 433. Kaemmerer M, Vigl M, Seifert-Klauss V, NagdymanN, Bauer U, Schneider KT, et al. Counseling reproductive health issues inwomenwith congenital heart disease. Clin Res Cardiol. 2012;101(11):901-7. 434. Vigl M, Kaemmerer M, Seifert-Klauss V, Niggemeyer E, Nagdyman N, Trigas V, et al. Contraception in women with congenital heart disease. Am J Cardiol. 2010;106(9):1317-21. 435. Sobhani NC, Schultz H, Kheiwa A, Killion M, Parikh NI, Harris IS, et al. Contraceptive Choices in the Immediate Postpartum Period in Women With Cardiac Disease. Am J Cardiol. 2019;123(8):1364-9. 436. Federação Brasileira das Associaçoes de Ginecologia e Obstetricia [homepage na internet]. Anticoncepção para adolescentes [acesso em 11 out 2019]. Disponível em https://www.febrasgo.org.br/media/k2/ attachments/15-anticoncepção para adolescentes.pdf. 941